HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
View All | Scroll Down Scroll Up
Quote:
Login Free Membership
Search:

Analyst Blog  

Buy Cypress Bioscience

Share
December 19, 2008 |Comments: 0
Recommended this article (0)
CYPR

With a data from a third positive phase III trial in fibromyalgia released in early December 2008, we are feeling confident that the FDA will approval Cypress Bioscience, Inc.'s (CYPR) and partner Forest Laboratories, Inc. (FRX) milnacipran product during the first quarter of 2009.

Approval of milnacipran will be a transformational event for Cypress. The company should become almost immediately profitable based on royalties from Forest Labs. By 2013 we see total revenues exceeding $110 million, with net margins above 50%.

We see fair value at $12 per share, or 25x our 2012 EPS estimate of $1.12 per share, discounted back to present day.

Read the full analyst report on CYPR

Read the full analyst report on FRX


Read the full analyst report on CYPR

 
Add a Comment

Please login or register to post a comment

Email
Print
Share
Rate Pos
Rate Neg
Comment

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

More Zacks Links

Market Summary Feb 10, 2012 14:05 pm ET
DJIA 12764.98  -125.48 -0.97%
NASD 2903.16  -24.07 -0.82%
S&P 500 1340.09  -11.86 -0.88%
Partner Center

Top Zacks Features

Free Membership
Zacks Rank
Equity Research
Portfolio Tracker
Screening
Profit Tracks
Mutual Funds
Options
Zacks Video
Education
RSS Feed
Profit from the Pros

Subscription Services

Product Guide
Method for Trading
Chart Patterns Trader
Insider Trader
Options Trader
Reitmeister Alert
Small Cap Trader
Turnaround Trader
Whisper Trader
Home Run Investor
Top 10 Stocks
Research Wizard
Zacks Premium
People & Picks
Zacks.com: About Zacks | Education | Advertise | Affiliate | Media | Careers | Contact Us | Services | Help | Disclaimer | Privacy Policy | Sitemap

Copyright 2011 Zacks Investment Research

Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.